Lorlatinib/Lorlatinib resistance time

Lorlatinib/Lorlatinib is a selective tyrosine kinase receptor inhibitor used to treat patients with metastatic ALK positive mutations advanced non-small cell lung cancer . Larlatinib is associated with transient increases in serum aminotransferase levels during treatment.

Lorlatinib/The resistance time to lorlatinib varies from person to person. From relevant data, the average resistance time to lorlatinib is 14 months, and patients with intracranial metastasis have a longer resistance time. The usual dose of lorlatinib is 100 mg orally once daily until disease progression or unacceptable toxicity occurs. If the patient misses a dose, take the dose as soon as possible, but if the next dose is due within 4 hours, skip the missed dose and do not use two doses at once. Take lorlatinib exactly as prescribed by your doctor, follow all directions on the prescription label, and read any medication guides or inserts. Swallow the tablet whole without crushing, chewing or breaking it. Take the tablet at the same time every day with or without food. Do not use crushed or broken tablets. If a patient vomits shortly after taking lorlatinib, do not take another dose, wait until the next scheduled dose, and store at room temperature while taking it, away from moisture and high temperatures.

Do not change your dose or stop taking lorlatinib on your own. Do not use lorlatinib if the patient is pregnant. Patients may need to have a negative pregnancy test before starting this treatment and use effective birth control to prevent pregnancy while taking this medication and for at least 6 months after the last dose. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.